Evidence map›Paper›PMID 28710901›Full record

ArticleBJU international2018

Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.

Spyridon P Basourakos, John W Davis, Brian F Chapin, John F Ward, Curtis A Pettaway, Louis L Pisters, Neema Navai, Mary F Achim, Xuemei Wang, Hsiang-Chun Chen and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJU international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Spyridon P BasourakosDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John W DavisDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-3491-7194
Brian F ChapinDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John F WardDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Curtis A PettawayDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Louis L PistersDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neema NavaiDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mary F AchimDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xuemei WangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hsiang-Chun ChenDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Seungtaek ChoiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Deborah KubanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patricia TroncosoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sam HanashDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Timothy C ThompsonDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeri KimDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOGOTHETIS, CHRISTOPHER J., THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA140388
6 · The paper itself

Abstract

objectivesTo evaluate the role of caveolin-1 (Cav-1) as a predictor of disease reclassification (DR) in men with early prostate cancer undergoing active surveillance (AS). PATIENTS AND

methodsWe analysed archived plasma samples prospectively collected from patients with early prostate cancer in a single-institution AS study. Of 825 patients enrolled, 542 had ≥1 year of follow-up. Baseline and longitudinal plasma Cav-1 levels were measured using an enzyme-linked immunosorbent assay. Tumour volume or Gleason grade increases were criteria for DR. Logistic regression analyses were used to assess associations between clinicopathological characteristics and reclassification risk.

resultsIn 542 patients, 480 (88.6%) had stage cT1c disease, 542 (100.0%) had a median prostate-specific antigen level of 4.1 ng/mL, and 531 (98.0%) had a median Cancer of the Prostate Risk Assessment score of 1. In all, 473 (87.3%) had a Gleason score of 3+3. After a median of 3.1 years of follow-up, disease was reclassified in 163 patients (30.1%). The mean baseline Cav-1 level was 2.2 ± 8.5 ng/mL and the median 0.2 ng/mL (range, 0-85.5 ng/mL). In univariate analysis, baseline Cav-1 was a significant predictor for risk of DR (odds ratio [OR] 1.82, 95% confidence interval [CI] 1.24-2.65; P = 0.002). In multivariate analysis, with adjustments for age, tumour length, group risk stratification and number of positive cores, reclassification risk associated with Cav-1 remained significant (OR 1.91, 95% CI 1.28-2.84; P = 0.001).

conclusionBaseline plasma Cav-1 level was an independent predictor of disease classification. New methods for refining AS and intervention may result.

Indexed as

AgedAnalysis of VarianceBiomarkers, TumorCaveolin 1Cohort StudiesDisease ProgressionEnzyme-Linked Immunosorbent AssayHumansLogistic ModelsLongitudinal StudiesMaleMiddle AgedMultivariate AnalysisNeoplasm GradingPredictive Value of TestsPrognosisBiomarkers, TumorCaveolin 1Prostate-Specific Antigenactive surveillancebiomarkerscaveolin-1#PCSM#ProstateCancerwatchful waiting

Identifiers

PMID28710901
PMCPMC6126916
OpenAlexW2734835284

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.